Q-omics provides the consensus-scored TUBA8 profile across patient tissues and cancer cell-line models. TUBA8 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, TUBA8 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, TUBA8 protein abundance shows 22,994 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, KIRC, and GBM as cancer lineages where TUBA8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TUBA8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TUBA8 survival associations across molecular data types. TUBA8 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TUBA8 RNA expression–survival associations across cancer types. High TUBA8 expression shows unfavorable associations in UVM, COAD, ACC and KIRC, but favorable associations in CHOL and READ. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for TUBA8 RNA expression.
This table summarizes TUBA8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TUBA8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TUBA8 shows lower tumor expression in THCA and KICH and higher tumor expression in KIRC, LIHC, STAD and COAD. The KIRC box plot shows higher TUBA8 RNA expression in tumor versus normal tissue (log2 FC = +0.280, t-test p < 0.001).
This table shows molecular features associated with TUBA8 in patient tissues and cancer cell lines. In patient samples, TUBA8 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, TUBA8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and LARGE_INTESTINE.
